Tag: Financial Results

AI in Retail Industry to Reach USD 96.13B by 2030, Fueled by Personalization & Smart Store Automation – Reports Mordor Intelligence

HYDERABAD, India, Oct. 29, 2025 /PRNewswire/ — AI in Retail Market is projected to grow from USD 14.24 billion in 2025 to USD 96.13 billion by 2030, registering an exceptional CAGR of 46.54% during the forecast period (2025–2030). This exponential growth highlights the accelerating adoption of AI technologies across retail operations, from customer engagement and personalized… Continue reading AI in Retail Industry to Reach USD 96.13B by 2030, Fueled by Personalization & Smart Store Automation – Reports Mordor Intelligence

NLS Pharmaceutics Ltd. Announces 1-for-10 Reverse Share Split and Name Change in Connection with Proposed Merger with Kadimastem

ZURICH, Oct. 29, 2025 /PRNewswire/ — NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) (“NLS” or the “Company”), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced that it intends to effect a reverse share split of the Company’s issued and… Continue reading NLS Pharmaceutics Ltd. Announces 1-for-10 Reverse Share Split and Name Change in Connection with Proposed Merger with Kadimastem

Oppenheimer Announces the Appointment of Public Finance Banker Guy T. Logan as Managing Director, Head of Infrastructure & Mid-Atlantic Region

Addition of respected industry veteran highlights the rapid expansion of the firm’s Public Finance team NEW YORK, Oct. 29, 2025 /PRNewswire/ — Oppenheimer & Co. Inc. (“Oppenheimer”), a leading investment bank, wealth manager and a subsidiary of Oppenheimer Holdings (NYSE: OPY), today announced it has hired Guy T. Logan to serve as Managing Director, Head… Continue reading Oppenheimer Announces the Appointment of Public Finance Banker Guy T. Logan as Managing Director, Head of Infrastructure & Mid-Atlantic Region

Theravance Biopharma to Present Data on Ampreloxetine at the 36th International Symposium on The Autonomic Nervous System

Ampreloxetine clinical development program to be featured in four presentations at the upcoming International Symposium on The Autonomic Nervous System Topline results from the ongoing Phase 3 CYPRESS study of ampreloxetine anticipated in Q1 2026 DUBLIN, Oct. 29, 2025 /PRNewswire/ — Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced that it will be participating at the… Continue reading Theravance Biopharma to Present Data on Ampreloxetine at the 36th International Symposium on The Autonomic Nervous System

Aeson Power Sets New Safety and Performance Benchmark with Sodium-Ion Batteries at All-Energy Australia 2025

MELBOURNE, Australia, Oct. 29, 2025 /PRNewswire/ — Australian energy storage innovator Aeson Power is redefining battery safety, performance, and sustainability with the launch of its next-generation sodium-ion energy storage systems at All-Energy Australia 2025 in Melbourne. Following global success in automotive applications, Aeson Power’s polyanionic sodium-ion technology now enters the Australian off-grid, telecom, and commercial markets… Continue reading Aeson Power Sets New Safety and Performance Benchmark with Sodium-Ion Batteries at All-Energy Australia 2025

@niche: SLIDE TO NEW LIMITS WITH THE 2026 KTM 450 SMR004123

Dear Sir/Madam, Welcome to our Press Center. May we express our pleasure at the fact that you have chosen to use the pool of information regarding our company and its products and services. This information and content is made available by KTM Sportmotorcycle GmbH, Betriebsgebiet Süd, Stallhofner Straße 3, A-5230 Mattighofen, Austria, and we are… Continue reading @niche: SLIDE TO NEW LIMITS WITH THE 2026 KTM 450 SMR004123

Valmet’s Interim Review January 1 – September 30, 2025: Improving performance and landmark wins in a challenging market

Valmet Oyj’s stock exchange release on October, 29, 2025 at 9:00 a.m  EET ESPOO, Finland, Oct. 29, 2025 /PRNewswire/ —  Figures in brackets, unless otherwise stated, refer to the comparison period, i.e., the same period of the previous year.  July–September 2025: Orders received increased organically Orders received remained at the previous year’s level at EUR 1,083 million… Continue reading Valmet’s Interim Review January 1 – September 30, 2025: Improving performance and landmark wins in a challenging market

UPM Interim Report Q3 2025: UPM business portfolio delivered resilient performance in weak markets

HELSINKI, Oct. 29, 2025 /PRNewswire/ —  UPM-Kymmene Corporation Stock Exchange Release (Interim Report) October 29, 2025 at 9:30 EET Q3 2025 highlights Sales totaled €2,298 million (2,521 million in Q3 2024) Comparable EBIT decreased by 47% to €153 million, 6.7% of sales (291 million, 11.5%) Operating cash flow was €218 million (242 million) UPM initiated a strategic… Continue reading UPM Interim Report Q3 2025: UPM business portfolio delivered resilient performance in weak markets